News from synthetic biologics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 29, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Report Second Quarter Results on August 10, 2015

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jul 21, 2015, 09:24 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jul 16, 2015, 08:55 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Pricing of $40.0 Million Public Offering

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jul 15, 2015, 16:05 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Announces Public Offering of Common Stock

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jun 29, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation (IBS-C)

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jun 12, 2015, 06:58 ET
Synthetic Biologics, Inc. Logo.

First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jun 03, 2015, 06:28 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem Antibiotics

Synthetic Biologics, Inc. (NYSE MKT: SYN), this week presented initial data that support the Company's development of a platform of therapeutics...

Jun 02, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb, MD, FACG

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while...

Jun 01, 2015, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Host Microbiome Analyst & Investor Meeting

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting...

May 19, 2015, 09:30 ET
Synthetic Biologics, Inc. Logo. (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week® 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting...

May 18, 2015, 11:17 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting...

May 11, 2015, 16:01 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome...

May 07, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Maureen Early Named Vice President, Commercial of Synthetic Biologics

Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while...

May 04, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Steven Shallcross Named Chief Financial Officer of Synthetic Biologics

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapeutics focused on protecting the microbiome, as well as...

Apr 30, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics to Host First Quarter 2015 Investor Conference Call

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Apr 27, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a...

Apr 01, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 30, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 19, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 16, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...